MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.

MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process